The FDA approved Biogen s Qalsody (tofersen), a drug intended to treat amyotrophic lateral sclerosis with a rare mutation called the superoxide dismutase 1 gene, on April 25.
The Food and Drug Administration is not required to follow the panel's advice, but its positive recommendation suggests an approval is likely later this month.